This is a working overview of half-life, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Oclacitinib, sold under the brand name Apoquel among others, is a veterinary medication used in the control of atopic dermatitis and pruritus from allergic dermatitis in dogs at least 12 months of age. Chemically, it is a synthetic cyclohexylamino-pyrrolopyrimidine Janus kinase inhibitor (JAK inhibitor) that is relatively selective for JAK1. It inhibits signal transduction when the JAK is activated and thereby helps downregulate expression of inflammatory cytokine. Oclacitinib was approved for use in the United States in 2013 and in the European Union in 2023. A flavored chewable form was approved for use in the United States in 2023.
Food and Drug Administration concluded that TDA-induced breast cancer was an infinitesimal health-risk to women with breast implants, and did not justify legally requiring physicians to explain the matter to their patients. In the event, polyurethane-coated breast implants remain in plastic surgery practice in Europe and in South America; and no manufacturer has sought FDA approval for medical sales of such breast implants in the U.S.
== Release == Stargirl premiered on DC Universe on May 18, 2020, with the first season consisting of 13 episodes. The series was originally intended to premiere on May 11, seven days before its official release. The series was released in 4K Ultra HD on DC Universe. In November 2019, The CW announced to broadcast each episode the day after it premieres on the streaming service, with each episode available to stream on The CW's online platforms after its broadcast. Stargirl started airing on The CW on May 19, 2020, at 8 pm. Some episodes have content removed when they air on The CW to allow for the network's commercials, notably approximately eight minutes in each of the first two episodes. DC Universe streamed the full episodes, and Johns said starting with the third episode, both releases are "almost identical". The series release plans shifted and it stayed in post-production longer to accommodate the broadcast on The CW to accomplish the adjustments that had to be made. Scenes removed in the first episode from The CW broadcast included: establishing shots of Barbara Whitmore's new job, and Pat's auto shop; an interaction between Courtney and Cindy Burman in the halls of Blue Valley High School that Alex Zalben of Decider said was "clear set-up for later" but helped strengthen Courtney's emotional arc; and Mark Ashworth's scenes as "a mysterious, extremely creepy bearded janitor", which Zalben said was more of "a fun Easter egg that will pay dividends down the road"; and Courtney finding a newspaper article about Starman and Stripesy.
== Description == Eucalyptus globulus is a tree that typically grows to a height of 45 m (148 ft) but may sometimes only be a stunted shrub, or alternatively under ideal conditions can grow as tall as 90 m (300 ft), and forms a lignotuber. The bark is usually smooth, white to cream-coloured but there are sometimes slabs of persistent, unshed bark at the base. Young plants, often several metres tall, and coppice regrowth have stems that are more or less square in cross-section with a prominent wing on each corner. Juvenile leaves are mostly arranged in opposite pairs, sessile, glaucous elliptic to egg-shaped, up to 150 mm (5.9 in) long and 105 mm (4.1 in) wide. Adult leaves are arranged alternately, the same glossy to dark green on both sides, lance-shaped or curved, 150–300 mm (5.9–11.8 in) long and 17–30 mm (0.67–1.18 in) wide on a petiole 1.5–6 mm (0.059–0.236 in) long. The flower buds are arranged singly or in groups of three or seven in leaf axils, sometimes sessile or on a short thick peduncle. The individual buds are also usually sessile, sometimes on a pedicel up to 5 mm (0.20 in) long. Mature buds are top-shaped to conical, glaucous or green, with a flattened hemispherical, warty operculum with a central knob. Flowering time varies with subspecies and distribution but the flowers are always white. The fruit is a woody conical or hemispherical capsule 2–3 cm diameter with the valves close to rim level.
=== Weak base and weak coordinating anion === As perchloric acid is one of the strongest mineral acids, perchlorate is a very weak base in the sense of Brønsted–Lowry acid–base theory. As it is also generally a weakly coordinating anion, perchlorate is commonly used as a background, or supporting, electrolyte.
Sources: en.wikipedia.org
There was a large outbreak of eosinophilia-myalgia syndrome (EMS) in the U.S. in 1989, with more than 1,500 cases reported to the CDC and at least 37 deaths. After preliminary investigation revealed that the outbreak was linked to intake of tryptophan, the U.S. Food and Drug Administration (FDA) recalled tryptophan supplements in 1989 and banned most public sales in 1990, with other countries following suit. Subsequent studies suggested that EMS was linked to specific batches of L-tryptophan supplied by a single large Japanese manufacturer, Showa Denko. It eventually became clear that recent batches of Showa Denko's L-tryptophan were contaminated by trace impurities, which were subsequently thought to be responsible for the 1989 EMS outbreak. However, other evidence suggests that tryptophan itself may be a potentially major contributory factor in EMS. There are also claims that a precursor reached sufficient concentrations to form a toxic dimer. The FDA loosened its restrictions on sales and marketing of tryptophan in February 2001, but continued to limit the importation of tryptophan not intended for an exempted use until 2005. The fact that the Showa Denko facility used genetically engineered bacteria to produce the contaminated batches of L-tryptophan later found to have caused the outbreak of eosinophilia-myalgia syndrome has been cited as evidence of a need for "close monitoring of the chemical purity of biotechnology-derived products".
On the basis of favorable early results, ongoing research is examining proposed psychedelic therapies for conditions including major depressive disorder, and anxiety and depression linked to terminal illness. The United States Food and Drug Administration has granted breakthrough therapy status, which expedites the assessment of promising drug therapies for potential approval, to psilocybin therapy for treatment-resistant depression and major depressive disorder. It has been proposed that psychedelics used for therapeutic purposes may act as active "super placebos". On the other hand, the inverse placebo effect (or "knowcebo" effect) caused by blinding failure may create an illusion of large effect sizes with psychedelics.
In February 2013, the Australian Sports Anti-Doping Authority (ASADA) and the World Anti-Doping Agency (WADA) began an investigation into the legality of Essendon's supplements program during the 2012 AFL season and the preceding preseason. Thirty-four Essendon players—including Watson—were suspected of taking the banned peptide Thymosin beta-4. This quickly led to debate over whether or not a guilty verdict would see Watson stripped of the medal. The investigation and court action stretched over the following four years. Initially, the AFL Tribunal delivered a not guilty verdict in March 2015, but on appeal in the Court of Arbitration for Sport (CAS), the players were found guilty in January 2016, resulting in the suspensions of all thirty-four players. An appeal lodged against that decision in the Federal Supreme Court of Switzerland was dismissed in October 2016. Following the guilty verdict handed down by the CAS in January, it was announced the AFL Commission would meet in February to determine whether Watson would retain his Brownlow Medal; however, this decision was delayed until the outcome of the Federal Supreme Court appeal. The final decision regarding Jobe Watson's Brownlow medal win was decided by the AFL Commission in late November 2016, with Watson retrospectively ruled ineligible for the award, and the medal then awarded to the next highest vote-getters, Cotchin and Mitchell, under the normal rules regarding ineligible players; Watson had pre-empted the decision by announcing on 11 November 2016 that he would hand back the medal.
In Peru, this manifests in the worship of Pachamama, the earth and fertility goddess, who symbolizes the close connection to nature and reflects the collective unconscious of Andean culture. Canadian black metal band Panzerfaust used the Jungian concept of the 'Shadow' in the title of their 2024 record "To Shadow Zion"
Sources: en.wikipedia.org
2 NaNH2 + N2O → NaN3 + NaOH + NH3 These reactions are the basis of the industrial route, which produces about 250 tons per year in 2004, with production increasing due to the increased use of airbags.
== NAAS selected bibliography == 1955 Nuclear magnetic resonance saturation and rotary saturation in solids. Physical Review 98(6):1787–1809. 1959 With A. G. Anderson. Nuclear spin-lattice relaxation in metals. Physical Review 116(3):583–591. 1963. Pure nuclear electric quadrupole resonance in impure copper. Physical Review 130(2):589–595. 1963 With M. Eisenstadt. Nuclear spin relaxation by translational diffusion in solids. Physical Review 132(2):635–643. Pure nuclear electric quadrupole resonance in impure copper. Physical Review 130(2):589–595. 1965 The theory of relaxation processes. In Advances in Magnetic and Optical Resonance, pp. 1–32. 1967 Local-field mapping in mixed-state superconducting vanadium by nuclear magnetic resonance. Physical Review 162(2):367–374. 1969 Nuclear spin thermodynamics in the rotating frame. Science 164(3883):1015–1023. 1970 With R. K. Gupta. Double nuclear magnetic resonance observation of electron exchange between ferri- and ferrocytochrome c. Science 169(3951):1204–1206. 1971 With H. E. Bleich. Higher resolution NMR of rare spins in solids [1]. The Journal of Chemical Physics 55(11):5405–5406. 1971 With R. K. Gupta. Pulsed Fourier transform nuclear magnetic resonance spectrometer. In Advances in Magnetic and Optical Resonance, pp. 81–115. 1973 With A. Z. Genack. Nuclear spin diffusion and its thermodynamic quenching in the field gradients of a Type-II superconductor. Physical Review Letters 31(19):1204–1207. 1975 With S. D. Kunz and E. K. Ralph. Dynamic range in Fourier transform proton magnetic resonance.
Even before the Norman Conquest of England, the Normans had come into contact with Wales. Edward the Confessor had set up the aforementioned Ralph as Earl of Hereford and charged him with defending the Marches and warring with the Welsh. In these original ventures, the Normans failed to make any headway into Wales. After the Conquest, however, the Marches came completely under the dominance of William's most trusted Norman barons, including Bernard de Neufmarché, Robert Fitzhamon, Roger of Montgomery in Shropshire and Hugh Lupus in Cheshire. These Normans began a long period of slow conquest during which almost all of Wales was at some point subject to Norman interference. Norman words, such as baron (barwn), first entered Welsh at that time.
== Regulation of sulfur assimilation == Sulfur assimilation is highly regulated and influenced by both external environmental factors and internal metabolic feedback pathways, in order to maintain sulfur homeostasis. Under sulfur-deficient conditions, plants modify their internal pathways to enhance sulfur uptake. In plants, a key regulator is the transcription factor SLIM1 (Sulfur Limitation 1), which functions in activating genes involved in sulfur transport like SULTR1;2 (a high-affinity transporter) and those involved in sulfur assimilation like ATP sulfurylase and APS reductase. The post-transcriptional regulation of these genes are done via a microRNA called miR395. When sulfur uptake is sufficient and is no longer limited, this microRNA targets the SULTR2;1(a low-affinity transporter) and degrades/inhibits its translation. Besides the transcriptional regulation of sulfur assimilation, there also lies post-translational mechanisms that control this process. This includes feedback inhibition by the accumulation of end products such as glutathione and cysteine, as well as regulation of the enzyme APS reductase which is activated or inhibited by the redox state of the cell. In fungi, specifically the Aspergillus fumigatus, sulfur assimilation is managed by the transcription factor MetR. This transcription factor functions similarly to SLIM1, in which under sulfur-limiting conditions it activates genes responsible for sulfur uptake. MetR also plays a key role in protecting the fungus's virulence against the host-immune system.
=== The term chemotherapy === The word chemotherapy without a modifier usually refers to cancer treatment, but its historical meaning was broader. The term was coined in the early 1900s by Paul Ehrlich as meaning any use of chemicals to treat any disease (chemo- + -therapy), such as the use of antibiotics (antibacterial chemotherapy). Ehrlich was not optimistic that effective chemotherapy drugs would be found for the treatment of cancer. The first modern chemotherapeutic agent was arsphenamine, an arsenic compound discovered in 1907 and used to treat syphilis. This was later followed by sulfonamides (sulfa drugs) and penicillin. In today's usage, the sense "any treatment of disease with drugs" is often expressed with the word pharmacotherapy.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.